Immune evasion by a staphylococcal complement inhibitor that acts on C3 convertases

Area of Science:

• Immunology
• Microbiology
• Protein biochemistry

Background:

• The complement system is crucial for host defense but implicated in disease pathogenesis.
• Complement activation involves the formation of C3 convertases (C4b2a and C3bBb), essential for C3b deposition.
• Dysregulation of complement contributes to tissue injury and various inflammatory diseases.

Purpose of the Study:

• To identify and characterize a novel protein from Staphylococcus aureus that inhibits human complement activation.
• To elucidate the mechanism by which this protein interferes with complement pathways.
• To evaluate the therapeutic potential of this inhibitor as an anti-inflammatory agent.

Main Methods:

• Purification and characterization of staphylococcal complement inhibitor (SCI).
• Biochemical assays to assess SCI interaction with C3 convertases (C4b2a and C3bBb).
• Functional assays measuring C3b deposition and neutrophil-mediated phagocytosis and killing of Staphylococcus aureus.

Main Results:

• Identification of a 9.8-kilodalton excreted protein, staphylococcal complement inhibitor (SCI).
• SCI specifically binds and stabilizes human C3 convertases (C4b2a and C3bBb).
• SCI inhibits C3b deposition across classical, lectin, and alternative complement pathways, reducing Staphylococcus aureus opsonophagocytosis and killing by neutrophils.

Conclusions:

• Staphylococcal complement inhibitor effectively blocks complement activation by targeting C3 convertases.
• SCI's ability to inhibit complement-mediated inflammation and bacterial clearance suggests its potential as a novel anti-inflammatory therapeutic.
• The small, soluble nature and surface-acting mechanism of SCI make it a promising candidate for further development.